These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17943155)

  • 21. Survey of attitude of physicians on updates in the management of anemia in chronic kidney disease patients.
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):410-6. PubMed ID: 19414943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Change of hemoglobin level: causes and consequences. Renal anemia].
    Ryckelynck JP
    Nephrol Ther; 2008 Oct; 4 Spec No 2():9-16. PubMed ID: 19000893
    [No Abstract]   [Full Text] [Related]  

  • 23. [The effect of dialysis treatment on the oxygen affinity of hemoglobin in chronic kidney failure].
    Amor H; Humpeler E; Dittrich P
    Schweiz Med Wochenschr; 1974 Mar; 104(13):453-8. PubMed ID: 4824416
    [No Abstract]   [Full Text] [Related]  

  • 24. The Kidney Disease: improving Global Outcomes website: comparison of guidelines as a tool for harmonization.
    Vanbelleghem H; Vanholder R; Levin NW; Becker G; Craig JC; Ito S; Lau J; Locatelli F; Zoccali C; Solez K; Hales M; Lameire N; Eknoyan G
    Kidney Int; 2007 May; 71(10):1054-61. PubMed ID: 17377511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. It's time to compare anemia management strategies in hemodialysis.
    Coyne DW
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peritoneal dialysis adequacy during the r-Hu EPO treatment.
    Baranowska-Daca E; Ksiazek A
    Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():51-60. PubMed ID: 8192532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Red cell survival: relevance and mechanism involved.
    Handelman GJ; Levin NW
    J Ren Nutr; 2010 Sep; 20(5 Suppl):S84-8. PubMed ID: 20797578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic hepatitis ameliorates anaemia in haemodialysis patients.
    Lin YL; Lin CW; Lee CH; Lai IC; Chen HH; Chen TW
    Nephrology (Carlton); 2008 Jun; 13(4):289-93. PubMed ID: 18331433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential ultrafiltration and diffusion as alternative to conventional hemodialysis.
    Asaba H; Bergström J; Fürst P; Lindh K; Mion C; Oulès R; Shaldon S
    Proc Clin Dial Transplant Forum; 1976 Nov 19-22; 6():129-35. PubMed ID: 1029881
    [No Abstract]   [Full Text] [Related]  

  • 30. High hemoglobin in dialysis patients not receiving rHuEPO.
    Di Iorio B; Iodice C
    Am J Kidney Dis; 2002 Dec; 40(6):1349. PubMed ID: 12460061
    [No Abstract]   [Full Text] [Related]  

  • 31. Hemoglobin and 2,3-diphosphoglycerate levels in transfused dialysis patients with myocardial infarction.
    Crowley JP; Valeri CR; Metzger JB; Pono L; Chazan J
    Ann Clin Lab Sci; 1992; 22(1):11-7. PubMed ID: 1739269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The CARI guidelines. Biochemical and haematological targets. Haemoglobin.
    McMahon L;
    Nephrology (Carlton); 2008 Jul; 13 Suppl 2():S44-56. PubMed ID: 18713123
    [No Abstract]   [Full Text] [Related]  

  • 33. An economic evaluation of erythropoiesis-stimulating agents in CKD.
    Clement FM; Klarenbach S; Tonelli M; Wiebe N; Hemmelgarn B; Manns BJ
    Am J Kidney Dis; 2010 Dec; 56(6):1050-61. PubMed ID: 20932621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of recombinant human erythropoietin on hematological and hemostatic parameters with special reference to microhemolysis.
    Maurin N; Fitzner S; Fritz H; Gladziwa U; H agel J; Stefanidis I
    Clin Nephrol; 1995 Mar; 43(3):196-200. PubMed ID: 7774078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is it time to modify the target range for serum phosphorus levels in chronic kidney disease (CKD).
    Savica V; Bellinghieri G; Santoro D
    J Ren Nutr; 2010 Mar; 20(2):65. PubMed ID: 20185069
    [No Abstract]   [Full Text] [Related]  

  • 37. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment.
    Seiler S; Reichart B; Roth D; Seibert E; Fliser D; Heine GH
    Nephrol Dial Transplant; 2010 Dec; 25(12):3983-9. PubMed ID: 20525642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optical measurement of hematocrit and other biological constituents in renal therapy.
    Steuer RR; Bell DA; Barrett LL
    Adv Ren Replace Ther; 1999 Jul; 6(3):217-24. PubMed ID: 10452704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overview of regular dialysis treatment in Japan as of 31 December 2006.
    Nakai S; Masakane I; Akiba T; Shigematsu T; Yamagata K; Watanabe Y; Iseki K; Itami N; Shinoda T; Morozumi K; Shoji T; Marubayashi S; Morita O; Kimata N; Shoji T; Suzuki K; Tsuchida K; Nakamoto H; Hamano T; Yamashita A; Wakai K; Wada A; Tsubakihara Y
    Ther Apher Dial; 2008 Dec; 12(6):428-56. PubMed ID: 19140842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Should we modify hemoglobin targets in CKD patients? FDA and EMEA statements].
    Martín de Francisco AL; Aljama P; Arias M; Górriz JL; Martínez Castelao A; Portolés J
    Nefrologia; 2007; 27(4):399-404. PubMed ID: 17944575
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.